Braun, David A. http://orcid.org/0000-0003-4543-5553
Hou, Yue
Bakouny, Ziad http://orcid.org/0000-0003-1906-5704
Ficial, Miriam http://orcid.org/0000-0002-2005-9267
Sant’ Angelo, Miriam
Forman, Juliet
Ross-Macdonald, Petra
Berger, Ashton C.
Jegede, Opeyemi A.
Elagina, Liudmilla
Steinharter, John
Sun, Maxine
Wind-Rotolo, Megan
Pignon, Jean-Christophe
Cherniack, Andrew D.
Lichtenstein, Lee
Neuberg, Donna http://orcid.org/0000-0003-2566-3145
Catalano, Paul
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Sharpe, Arlene H. http://orcid.org/0000-0002-9736-2109
McDermott, David F. http://orcid.org/0000-0002-2675-5095
Van Allen, Eliezer M. http://orcid.org/0000-0002-0201-4444
Signoretti, Sabina
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Shukla, Sachet A. http://orcid.org/0000-0003-2445-3584
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Article History
Received: 22 December 2019
Accepted: 16 March 2020
First Online: 29 May 2020
Competing interests
: D.A.B. reported non-financial support from Bristol-Myers Squibb, honoraria from LM Education/Exchange Services, and personal fees from Octane Global, Defined Health, Dedham Group, Adept Field Solutions, Slingshot Insights, Blueprint Partnerships, Charles River Associates, Trinity Group, and Insight Strategy, outside of the submitted work. M.S. reported grants from Exelixis and Pfizer. G.J.F. and A.H.S. have patents/pending royalties on the PD-1 pathway from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Dako and Novartis. G.J.F. has equity in Nextpoint, Triursus, and Xios. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, NextPoint, and IgM. G.J.F. has received research funding from Bristol-Myers Squibb, outside of the submitted work. A.H.S. has served on advisory boards for Novartis, Surface Oncology, Elstar, SQZ Biotechnologies, Adaptimmune, Elpiscience, Monopteros. A.H.S. has received research funding from Novartis, Roche, UCB, Ipsen, Quark and Merck. D.F.M. reported personal fees from Bristol-Myers Squibb, Pfizer, Merck, Novartis, Exelixis, Array BioPharm, Genentech, Alkermes, Jounce Therapeutics, X4 Pharma, Peloton, EMD Serono, and Eli Lilly; research support from Bristol-Myers Squibb, Prometheus Laboratories, Merck, Genentech, Pfizer, Exelixis, Novartis, X4 Pharma, Alkermes, and Peloton. E.M.V.A. had a patent to the association of mutations in <i>PBAF</i> genes and response to cancer immunotherapy pending. E.M.V.A. reported personal fees from Tango Therapeutics, Genome Medical, Invitae, Illumina, and Dynamo; grants from Novartis, Bristol-Myers Squibb-IION, nonfinancial support from Genentech, personal fees from Synapse and Microsoft outside the submitted work. S.S. reported personal fees from Merck, AstraZeneca, Bristol-Myers Squibb, AACR, and NCI, grants from Bristol-Myers Squibb, AstraZeneca, Novartis, and Exelixis, and royalties from Biogenex. C.J.W. is a founder and equity holder of Neon Therapeutics and a member of its scientific advisory board. S.A.S. reported nonfinancial support from Bristol-Myers Squibb outside the submitted work. S.A.S. previously advised and has received consulting fees from Neon Therapeutics. S.A.S. reported nonfinancial support from Bristol-Myers Squibb, and equity in Agenus Inc., Agios Pharmaceuticals, Breakbio Corp., Bristol-Myers Squibb and NewLink Genetics, outside the submitted work. T.K.C. reported grants and personal fees from AstraZeneca, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Cerulean, grants and personal fees from Eisai, personal fees from Foundation Medicine Inc, grants and personal fees from Exelixis, grants and personal fees from Genentech, personal fees from Roche, grants and personal fees from GlaxoSmithKline, grants and personal fees from Merck, from Novartis, Peloton, and Pfizer, personal fees from Prometheus Labs, grants and personal fees from Corvus, personal fees from Ipsen, grants from Tracon, grants from Astellas outside the submitted work. The other authors declare no conflicts of interest.